TrinetX Study of Hypereosinophilic Syndrome (HES) without an identifiable non-haematological secondary cause

Exclusion Criteria

• - Any mutation in PDGFRA, PDGFRB or FGFR1 genes (to exclude clonal HES).
• - History of BCR-ABL tyrosine kinase inhibitor use: imatinib, dasatinib, nolitinib, bosutinib, ponatinib, asciminib (to exclude clonal HES)
• - History of myeloid leukemia, myeloproliferative disorder, myelodysplastic disorder, myelomonocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukaemia, acute panmyelosis with myelofibrosis, and other specified leukaemias (to exclude reactive HES)
• - History of helminthiasis or use of anthelmintic medication (to exclude reactive HES)
• - History of autoimmune disease (to exclude reactive HES)
• - History of use of specific drugs: antiepileptics, sulfonamides, allopurinol, and immune checkpoint inhibitors (to exclude reactive HES)